annual meeting program - American Society of Clinical Oncology

TUESDAY
Tuesday, June 8, 2010
8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION
Lung Cancer—Local-Regional and Adjuvant Therapy
Display Time: 8:00 AM - 12:00 PM
Display Location: E450b
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: E354b
CME credit: 1
Track(s): Lung Cancer
Joseph Kamel Salama, MD—Co-Chair
The University of Chicago
Corey J. Langer, MD—Co-Chair
University of Pennsylvania
Discussion
12:00 PM John Heymach, MD, PhD (Abstracts #7008–7013)
University of Texas M. D. Anderson Cancer Center
Biomarkers in Early-stage Non-small Cell Lung Cancer: Has the Future Arrived?
Discussion
12:15 PM Jeffrey Bogart, MD (Abstracts #7014–7016)
SUNY Upstate Medical University
New Directions for Radiotherapy in Non-small Cell Lung Cancer
Discussion
12:30 PM William Roy Smythe, MD (Abstracts #7017–7020)
Texas A&M University
Surgical Perspective on Systemic Therapy for NSCLC and Mesothelioma
Discussion
12:45 PM Jessica S. Donington, MD (Abstracts #7021–7026)
New York University School of Medicine
Alternate Approaches to Advanced, Resectable Non-small Cell Lung Cancer
Brd. 1 Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically
resected stage IB NSCLC: CALGB 9633. (Abstract #7008)
M. Capelletti, X. F. Wang, L. Gu, S. L. Graziano, R. A. Kratzke, G. M. Strauss,
M. Maddaus, M. R. Green, E. E. Vokes, P. A. Janne
Brd. 2 Initial results of LC-MAP: An institutional program to routinely profile tumor
specimens for the presence of mutations in targetable pathways in all
patients with lung adenocarcinoma. (Abstract #7009)
M. G. Kris, C. Y. Lau, D. Ang, E. Brzostowski, G. J. Riely, V. W. Rusch,
S. Jhanwar, A. Lash, M. F. Zakowski, M. Ladanyi
Brd. 3 Association of genetic variations in DNA-methyltransferases, histonemethyltransferases,
and methylated DNA-binding proteins with recurrence
and survival in early-stage non-small cell lung cancer treated with surgery
alone or surgery and chemotherapy. (Abstract #7010)
K. W. Wagner, Y. Ye, J. Lin, A. A. Vaporciyan, J. A. Roth, M. R. Spitz, X. Wu
Brd. 4 Impact of EGFR and KRAS mutations on survival in 1,000 patients with
resected lung adenocarcinoma. (Abstract #7011)
S. P. D’Angelo, Y. Y. Janjigian, M. G. Kris, W. Pao, G. J. Riely, J. Marks, C. Sima,
J. Dycoco, B. J. Park, C. G. Azzoli
Brd. 5 Clinical relevance of insulin regulatory pathways in non-small cell lung
cancer (NSCLC) progression. (Abstract #7012)
Y. Bellil, A. M. Burke, I. S. Chan, W. Mostertz, A. Potti
Brd. 6 KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim
analysis of S0424. (Abstract #7013)
P. C. Mack, M. W. Redman, K. Chansky, S. Matsumoto, W. S. Holland, P. Lara Jr.,
C. B. Ambrosone, D. R. Gandara
430